MA63589B1 - Dérivés d'alpha-d-galactopyranoside substitués par triazolyl-méthyle - Google Patents
Dérivés d'alpha-d-galactopyranoside substitués par triazolyl-méthyleInfo
- Publication number
- MA63589B1 MA63589B1 MA63589A MA63589A MA63589B1 MA 63589 B1 MA63589 B1 MA 63589B1 MA 63589 A MA63589 A MA 63589A MA 63589 A MA63589 A MA 63589A MA 63589 B1 MA63589 B1 MA 63589B1
- Authority
- MA
- Morocco
- Prior art keywords
- triazolyl
- methyl substituted
- substituted alpha
- galactopyranoside
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/06—Heterocyclic radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2021055348 | 2021-03-03 | ||
| EP22708569.3A EP4301748B1 (en) | 2021-03-03 | 2022-03-02 | Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives |
| PCT/EP2022/055224 WO2022184755A1 (en) | 2021-03-03 | 2022-03-02 | Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA63589B1 true MA63589B1 (fr) | 2025-07-31 |
Family
ID=80682779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA63589A MA63589B1 (fr) | 2021-03-03 | 2022-03-02 | Dérivés d'alpha-d-galactopyranoside substitués par triazolyl-méthyle |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20240109930A1 (https=) |
| EP (1) | EP4301748B1 (https=) |
| JP (1) | JP7771205B2 (https=) |
| KR (1) | KR20230154221A (https=) |
| CN (1) | CN116888113A (https=) |
| AU (1) | AU2022228660A1 (https=) |
| BR (1) | BR112023017624A2 (https=) |
| CA (1) | CA3209917A1 (https=) |
| CL (1) | CL2023002578A1 (https=) |
| ES (1) | ES3033422T3 (https=) |
| HR (1) | HRP20250833T1 (https=) |
| HU (1) | HUE072194T2 (https=) |
| IL (1) | IL305581A (https=) |
| MA (1) | MA63589B1 (https=) |
| MX (1) | MX2023010241A (https=) |
| PL (1) | PL4301748T3 (https=) |
| RS (1) | RS67032B1 (https=) |
| TW (1) | TWI905393B (https=) |
| UA (1) | UA130562C2 (https=) |
| WO (1) | WO2022184755A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114206893A (zh) | 2019-08-09 | 2022-03-18 | 爱杜西亚药品有限公司 | (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物 |
| WO2021028323A1 (en) | 2019-08-09 | 2021-02-18 | Idorsia Pharmaceuticals Ltd | (2-acetamidyl)thio-beta-d-galactopyranoside derivatives |
| MA56883B1 (fr) | 2019-08-15 | 2025-04-30 | Idorsia Pharmaceuticals Ltd | Dérivés de 2-hydroxycycloalcane-1-carbamoyle |
| CN114585619B (zh) | 2019-08-29 | 2024-09-27 | 爱杜西亚药品有限公司 | α-D-吡喃半乳糖苷衍生物 |
| US12312362B2 (en) | 2020-10-06 | 2025-05-27 | Idorsia Pharmaceuticals Ltd | Spiro derivatives of Alpha-D-galactopyranosides |
| EP4237419A1 (en) | 2020-11-02 | 2023-09-06 | Idorsia Pharmaceuticals Ltd | Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives |
| CN116806219A (zh) | 2021-02-09 | 2023-09-26 | 爱杜西亚药品有限公司 | 羟基杂环烷-氨甲酰基衍生物 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100172D0 (sv) | 2001-01-22 | 2001-01-22 | Ulf Nilsson | New inhibitors against galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| SE0401301D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| DK2906227T3 (en) | 2012-10-10 | 2018-12-10 | Galectin Therapeutics Inc | GALACTOSE-CONTAINING CARBOHYDRATE COMPOUNDS FOR THE TREATMENT OF DIABETIC Nephropathy |
| CN104755088A (zh) | 2012-10-31 | 2015-07-01 | 格莱克特生物技术公司 | 半乳凝集素-3的半乳糖苷抑制剂及其用于治疗肺纤维化的应用 |
| EP2919802A4 (en) | 2012-11-15 | 2016-09-14 | Univ Tufts | METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER |
| CA2970062C (en) | 2015-01-30 | 2023-02-28 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| PL3456717T3 (pl) | 2015-07-06 | 2021-10-25 | Gilead Sciences, Inc. | Pochodna 4,6-diaminochinolino-3-karbonitrylu jako modulator cot (cancer osaka thyroid) do leczenia choroby zapalnej |
| EP3621973A4 (en) | 2017-05-12 | 2021-10-27 | Galectin Sciences, LLC | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES AND USES THEREOF |
| KR20200015528A (ko) | 2017-05-12 | 2020-02-12 | 갈랙틴 사이언시즈, 엘엘씨 | 전신 인슐린 내성 질환의 치료용 화합물 및 그의 용도 |
| WO2019067702A1 (en) * | 2017-09-27 | 2019-04-04 | Bristol-Myers Squibb Company | INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3 |
| US11072626B2 (en) | 2017-10-11 | 2021-07-27 | Bristol-Myers Squibb Company | Small molecule inhibitors of Galectin-3 |
| CA3080128A1 (en) | 2017-10-31 | 2019-05-09 | Galectin Sciences, Llc | Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof |
| WO2020104335A1 (en) | 2018-11-21 | 2020-05-28 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| US12269819B2 (en) * | 2019-04-10 | 2025-04-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of Galectin-3 |
| JP7674276B2 (ja) | 2019-07-03 | 2025-05-09 | ガレクト バイオテック エービー | ガレクチンの新規なガラクトシド阻害剤 |
| WO2021004940A1 (en) | 2019-07-05 | 2021-01-14 | Galecto Biotech Ab | Novel galactoside inhibitor of galectins |
| WO2021028323A1 (en) | 2019-08-09 | 2021-02-18 | Idorsia Pharmaceuticals Ltd | (2-acetamidyl)thio-beta-d-galactopyranoside derivatives |
| CN114206893A (zh) | 2019-08-09 | 2022-03-18 | 爱杜西亚药品有限公司 | (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物 |
| MA56883B1 (fr) | 2019-08-15 | 2025-04-30 | Idorsia Pharmaceuticals Ltd | Dérivés de 2-hydroxycycloalcane-1-carbamoyle |
| CN114585619B (zh) | 2019-08-29 | 2024-09-27 | 爱杜西亚药品有限公司 | α-D-吡喃半乳糖苷衍生物 |
-
2022
- 2022-03-02 RS RS20250732A patent/RS67032B1/sr unknown
- 2022-03-02 PL PL22708569.3T patent/PL4301748T3/pl unknown
- 2022-03-02 WO PCT/EP2022/055224 patent/WO2022184755A1/en not_active Ceased
- 2022-03-02 AU AU2022228660A patent/AU2022228660A1/en active Pending
- 2022-03-02 HR HRP20250833TT patent/HRP20250833T1/hr unknown
- 2022-03-02 UA UAA202304634A patent/UA130562C2/uk unknown
- 2022-03-02 BR BR112023017624A patent/BR112023017624A2/pt unknown
- 2022-03-02 ES ES22708569T patent/ES3033422T3/es active Active
- 2022-03-02 KR KR1020237033375A patent/KR20230154221A/ko active Pending
- 2022-03-02 IL IL305581A patent/IL305581A/en unknown
- 2022-03-02 US US18/548,833 patent/US20240109930A1/en active Pending
- 2022-03-02 EP EP22708569.3A patent/EP4301748B1/en active Active
- 2022-03-02 CA CA3209917A patent/CA3209917A1/en active Pending
- 2022-03-02 MA MA63589A patent/MA63589B1/fr unknown
- 2022-03-02 TW TW111107565A patent/TWI905393B/zh active
- 2022-03-02 JP JP2023552539A patent/JP7771205B2/ja active Active
- 2022-03-02 MX MX2023010241A patent/MX2023010241A/es unknown
- 2022-03-02 HU HUE22708569A patent/HUE072194T2/hu unknown
- 2022-03-02 CN CN202280017484.3A patent/CN116888113A/zh active Pending
-
2023
- 2023-08-31 CL CL2023002578A patent/CL2023002578A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3209917A1 (en) | 2022-09-09 |
| PL4301748T3 (pl) | 2025-09-08 |
| WO2022184755A1 (en) | 2022-09-09 |
| TW202300146A (zh) | 2023-01-01 |
| TWI905393B (zh) | 2025-11-21 |
| AU2022228660A1 (en) | 2023-10-19 |
| EP4301748A1 (en) | 2024-01-10 |
| HRP20250833T1 (hr) | 2025-09-12 |
| MX2023010241A (es) | 2023-09-12 |
| CL2023002578A1 (es) | 2024-03-22 |
| CN116888113A (zh) | 2023-10-13 |
| US20240109930A1 (en) | 2024-04-04 |
| EP4301748B1 (en) | 2025-05-07 |
| UA130562C2 (uk) | 2026-03-18 |
| JP2024509421A (ja) | 2024-03-01 |
| IL305581A (en) | 2023-10-01 |
| BR112023017624A2 (pt) | 2023-10-10 |
| EP4301748C0 (en) | 2025-05-07 |
| RS67032B1 (sr) | 2025-08-29 |
| JP7771205B2 (ja) | 2025-11-17 |
| KR20230154221A (ko) | 2023-11-07 |
| HUE072194T2 (hu) | 2025-10-28 |
| ES3033422T3 (en) | 2025-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA63589B1 (fr) | Dérivés d'alpha-d-galactopyranoside substitués par triazolyl-méthyle | |
| MA58498B1 (fr) | Agonistes hétérocycliques de glp-1 | |
| MA56883B1 (fr) | Dérivés de 2-hydroxycycloalcane-1-carbamoyle | |
| JOP20230113A1 (ar) | مشتقات ثلاثية الكربوكساميد كمثبطات prmt5 | |
| MX2023001379A (es) | Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a. | |
| MA52360B1 (fr) | Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines | |
| MA67365B1 (fr) | Dérivés de benzisoxazole sulfonamide | |
| MA29926B1 (fr) | Derives de pyrazine | |
| JOP20230138A1 (ar) | مثبطات prmt5 | |
| TNSN07022A1 (fr) | Derives de pyridine | |
| MA54608B1 (fr) | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
| TN2009000450A1 (fr) | Derives de pyridine | |
| MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA54653B1 (fr) | Modulateurs du récepteur de cxcr7 pipéridine | |
| MA55046B1 (fr) | Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2 | |
| MA27093A1 (fr) | Derives de sulfonamides, leur preparation et leur application comme medicaments. | |
| MX2022015886A (es) | Derivados de amidopirimidona. | |
| MA34819B1 (fr) | Dérivés bicyclo[3.2.1]octylamide et leurs utilisations | |
| MA27559A1 (fr) | Nouveaux derives de fluorglycoside aromatiques, produits pharmaceutiques contenant ces composes et leur utilisation | |
| MA57000B1 (fr) | Dérivés d'alpha-d-galactopyranoside | |
| MA56526B1 (fr) | Dérivés de pyrido [2,3-d] pyrimidine en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine | |
| MA49127B1 (fr) | Dérivés d'indole n-substitués | |
| MA31080B1 (fr) | Dérivés cyclisés en tant qu'inhibiteurs d'eg-5. | |
| MA27867A1 (fr) | Nouveaux derives de 2h-pyridazine-3-one, compositions pharmaceutiques contenant ces derives et procede de preparation de l'ingredient actif. | |
| MA30959B1 (fr) | Composes de pyrazole et de triazole substitues comme inhibiteurs de ksp |